Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib

September 8, 2011
Eisai announced on September 7 that it had entered a joint development agreement with SFJ Pharma (SFJ), a subsidiary of US drug development company SFJ Pharmaceuticals on September 1. Under the terms of the agreement, SFJ Pharma will supply funding...read more